Patient Characteristics
Of Confirm Rx devices implanted in the U.S. between April 2018 and March 2020, 1,000 devices were randomly selected in June 2020 (48.5% male, age 71 [61, 78] years). Of those, 869 devices with at least 90 days of transmission history were included in the analysis. Of those 869 devices, 644 devices transmitted a total of 95,716 arrhythmia EGMs, 177 devices transmitted only symptom EGMs, and the remaining 48 devices transmitted no EGMs. The number of EGMs corresponding to each arrhythmia type, and the number of devices that transmitted those EGMs, are provided in Table 1 . The 644 devices associated with at least one arrhythmia EGM transmitted 4.1 [0.7, 19.3] EGMs/patient/month of all arrhythmia types across a follow-up duration of 8.1 [5.5, 10.9] months, for a total of 34.0 [5.0, 141.5] EGMs/patient. The patient distribution by reason for monitoring is provided in Table 2 . Devices were predominantly implanted due to syncope (34.3%), suspected AF (22.0%), or cryptogenic stroke (18.6%).